Genomic correlates of clinical outcome in advanced prostate cancer
Memorial Sloan Kettering Cancer Center · University of Bern · +13 more institutions
Abstract
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including…
Citation impact
- FWCI
- 109.89
- Percentile
- 100%
- References
- 45
Authors
43Topics & keywords
- Enzalutamide
- Prostate cancer
- Androgen receptor
- Transcriptome
- Abiraterone
- Exome
- Oncology
- Abiraterone acetate
- No poverty